Guardant Health (GH) on Thursday shared data for its Shield V2 algorithm update, saying overall sensitivity increased to 84% from 83%, a modest shortfall vs. bullish takes looking for a metric approaching high 80s, Raymond James analyst Andrew Cooper tells investors. The firm, which has an Outperform rating on the stock, believes the double digit lows touched Thursday morning are a “bit” overdone, and says Guardant remains in the lead in blood-based CGP and tumor-free MRD, both large and growing opportunities in their own rights.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health falls -8.3%
- Cathie Wood Continues to Sell Roku, Invests $13M in CRISPR and Intellia
- Cathie Wood Sells Shopify and Coinbase Stocks, Adds to PagerDuty (PD) Stake
- Cathie Wood Buys $172M Worth of Bullish Stock (BLSH) on Blockbuster IPO Debut, Trims Stake in SHOP
- Cathie Wood ‘Buys the Dip’ in Block Stock; Sells Shopify Shares